参考文献/References:
[1] Pryor R,Martinez-Martinez D,Quintaneiro L,et al.The role of the microbiome in drug response[J].Annu Rev Pharmacol Toxicol,2020,60:417-435.DOI: 10.1146/annurev-pharmtox-010919-023612.
[2] Gribble FM,Reimann F.Function and mechanisms of enteroendocrine cells and gut hormones in metabolism[J].Nat Rev Endocrinol,2019,15(4):226-237.DOI:10.1038/s41574-019-0168-8.
[3] Brønden A,Knop FK.Gluco-metabolic effects of pharmacotherapy-induced modulation of bile acid physiology[J].J Clin Endocrinol Metab,2020,105(1): dgz025.DOI:10.1210/clinem/dgz025.
[4] Kyriachenko Y,Falalyeyeva T,Korotkyi O,et al.Crosstalk between gut microbiota and antidiabetic drug action[J].World J Diabetes,2019,10(3):154-168.DOI:10.4239/wjd.v10.i3.154.
[5] Wu H,Esteve E,Tremaroli V,et al.Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes,contributing to the therapeutic effects of the drug[J].Nat Med,2017,23(7):850-858.DOI:10.1038/nm.4345.
[6] de la Cuesta-Zuluaga J,Mueller NT,Corrales-Agudelo V,et al.Metformin is associated with higher relative abundance of mucin-degrading akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut[J].Diabetes Care,2017,40(1):54-62.DOI:10.2337/dc16-1324.
[7] Vallianou NG,Stratigou T,Tsagarakis S.Metformin and gut microbiota: their interactions and their impact on diabetes[J].Hormones(Athens),2019,18(2):141-144.DOI:10.1007/s42000-019-00093-w.
[8] Sanna S,van Zuydam NR,Mahajan A,et al.Causal relationships among the gut microbiome,short-chain fatty acids and metabolic diseases[J].Nat Genet, 2019,51(4):600-605.DOI:10.1038/s41588-019-0350-x.
[9] Sun L,Xie C,Wang G,et al.Gut microbiota and intestinal FXR mediate the clinical benefits of metformin[J].Nat Med,2018,24(12):1919-1929.DOI:10.1038/s41591-018-0222-4.
[10] Chávez-Talavera O,Tailleux A,Lefebvre P,et al.Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease[J].Gastroenterology,2017,152(7):1679-1694.e3.DOI:10.1053/j.gastro.2017.01.055.
[11] Zhang X,Fang Z,Zhang C,et al.Effects of acarbose on the gut microbiota of prediabetic patients:a randomized,double-blind,controlled crossover trial[J].Diabetes Ther,2017,8(2):293-307.DOI:10.1007/s13300-017-0226-y.
[12] Yan X,Feng B,Li P,et al.Microflora disturbance during progression of glucose intolerance and effect of sitagliptin:an animal study[J].J Diabetes Res,2016,2016:2093171.DOI:10.1155/2016/2093171.
[13] Olivares M,Schüppel V,Hassan AM,et al.The potential role of the dipeptidyl peptidase-4-like activity from the gut microbiota on the host health[J].Front Microbiol,2018,9:1900.DOI:10.3389/fmicb.2018.01900.
[14] Lee DM,Battson ML,Jarrell DK,et al.SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice[J].Cardiovasc Diabetol,2018,17(1):62.DOI:10.1186/s12933-018-0708-x.
[15] Madsen MSA,Grønlund RV,Eid J,et al.Characterization of local gut microbiome and intestinal transcriptome responses to rosiglitazone treatment in diabetic db/db mice[J].Biomed Pharmacother,2021,133:110966.DOI:10.1016/j.biopha.2020.110966.
[16] Li D,Feng Y,Tian M,et al.Gut microbiota-derived inosine from dietary barley leaf supplementation attenuates colitis through PPARγ signaling activation[J].Microbiome,2021,9(1):83.DOI:10.1186/s40168-021-01028-7.
[17] 刘率男,刘泉,刘玉玲,等.桑枝总生物碱片研发历程回顾(二):现代药理学理念诠释中药的药效特点及药理作用机制[J].中国糖尿病杂志,2020,28(8):635-640.DOI:10.3969/j.issn.1006-6187.2020.08.015.
[18] Habtemariam S.Berberine pharmacology and the gut microbiota:a hidden therapeutic link[J].Pharmacol Res,2020,155:104722.DOI:10.1016/j.phrs.2020.104722.
[19] Forslund K,Hildebrand F,Nielsen T,et al.Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota[J].Nature,2015,528(7581):262-266.DOI:10.1038/nature15766.
[20] Bryrup T,Thomsen CW,Kern T,et al.Metformin-induced changes of the gut microbiota in healthy young men:results of a non-blinded, one-armed intervention study[J].Diabetologia,2019,62(6):1024-1035.DOI:10.1007/s00125-019-4848-7.
相似文献/References:
[1]曾静波,王姮.2型糖尿病与自身免疫反应[J].国际内分泌代谢杂志,2007,(04):259.
[2]朱素君,谢锦桃,刘军,等.二甲双胍：2型糖尿病治疗的基础药[J].国际内分泌代谢杂志,2007,(04):280.
[3]刘艳清 易秋艳 邵加庆.肠道菌群与肥胖和糖尿病的关系[J].国际内分泌代谢杂志,2015,(01):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
Liu Yanqing,Yi Qiuyan,Shao Jiaqing..Relationship between gut microbiota, obesity and diabetes[J].International Journal of Endocrinology and Metabolism,2015,(01):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
[4]姚旻 赵爱源 张宏.肠道菌群与2型糖尿病[J].国际内分泌代谢杂志,2015,(01):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
Yao Min*,Zhao Aiyuan,Zhang Hong..Relationship between gut microbiota and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(01):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
[5]赵丽娟,徐宽枫,杨涛,等.SLC30A8和PTPRD基因多态性与南京地区中老年人群2型糖尿病的相关性研究[J].国际内分泌代谢杂志,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
Zhao Lijuan*,Xu Kuanfeng,Yang Tao,et al.Relationship between SLC30A8 and PTPRD gene polymorphisms and type 2 diabetes in middle aged and elderly people in Nanjing area[J].International Journal of Endocrinology and Metabolism,2015,(01):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
[6]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[7]刘帅,张萍,方毅,等.2型糖尿病合并无症状冠状动脉钙化的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
Liu Shuai*,Zhang Ping,Fang Yi,et al.Analysis of the risk factors related with asymptomatic coronary calcification for type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(01):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
[8]徐庆海,马颖,李铁马.2型糖尿病患者高甘油三酯血症-腰围表型与甲状腺功能异常的关系[J].国际内分泌代谢杂志,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
Xu Qinghai,Ma Ying,Li Tiema..Association of hypertriglyceridaemic-waist phenotype with thyroid dysfunction in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(01):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
[9]潘道延,沈洁,朱筱,等.利格列汀对2型糖尿病大鼠代谢性内毒素血症的影响[J].国际内分泌代谢杂志,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
Pan Daoyan,Shen Jie,Zhu Xiao,et al.Effects of linagliptin on metabolic endotoxemia in type 2 diabetic rats[J].International Journal of Endocrinology and Metabolism,2015,(01):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
[10]黄桥,白洁,杜洪泉.一种新的脂肪细胞因子——cartonectin[J].国际内分泌代谢杂志,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]
Huang Qiao*,Bai Jie,Du Hongquan..A novel adipokine--cartonectin[J].International Journal of Endocrinology and Metabolism,2015,(01):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]